cyrilzakka/clinical-trials huggingface dataset:
New Technological Pathway for Gait Rehabilitation

\*\*Brief Summary\*\*

The study aims to explore how the integration of visual and motor systems can be trained and enhanced to improve gait rehabilitation in patients with various neurological and cardiovascular conditions. Scientific evidence highlights that physical activity requires coordination and precise processing of visual, auditory, and sensory information from the external environment, which is then integrated at the brain level. This process establishes synaptic connections that direct the movement of arms, hands, legs, and the trunk through bottom-up and top-down mechanisms. However, inaccurate or incomplete perceptual information can impair performance, even when accurate visual stimuli are provided, emphasizing the importance of assessing and enhancing visuo-motor integration.

The research investigates the central mechanisms controlling peripheral muscle activation patterns during gait. While over-ground walking in healthy individuals generally does not activate the prefrontal cortex except in dual-task scenarios, evidence suggests that post-stroke patients exhibit increased prefrontal cortex metabolism during walking. Recent studies have shown that gait training with exoskeletal systems improves walking patterns in post-stroke patients by altering muscle activation patterns and increasing fronto-parietal connectivity.

This study seeks to answer the following question: How do central and peripheral mechanisms interact to influence gait rehabilitation outcomes, and what role do visuo-motor integration and neuroplasticity play in this process? To address this, advanced neuroimaging technologies such as fMRI, dtMRI, and NIRS will be employed to investigate these mechanisms in vivo.


Eligibility Criteria:
Inclusion Criteria:

* Patients with a Montreal Cognitive Assessment (MoCA) score, corrected for age and education, equal to or greater than 20.
* Subjects capable of walking independently (Functional Ambulation Categories - FAC \> 2).

Exclusion Criteria:

* Cognitive impairments that compromise the understanding and/or execution of the proposed exercises.
* Associated comorbidities that prevent maintaining an upright position or walking (e.g., hypotension).
* Refusal or inability to provide informed consent.
* Patients with contraindications to the use of the technological equipment required for the dynamic movement pathway.
A Very Early Standing Study in Elderly Stroke

Functional recovery is one of the main issues in the management of stroke and there are various ways in rehabilitation to promote this recovery.

Verticalization is a technique whose benefits have been widely demonstrated, particularly in neurology. Although commonly used in the rehabilitation of stroke, evidence is still lacking as to its impact in this specific care.

Verticalization is underutilized in two situations: in the hyper acute phase as well as in elderly and very deficient patients. It has, however, been shown that the precocity of the treatment allows a better functional recovery. Similarly, the re-education of the elderly is also debated since it has long been mentioned that age was a factor of poor prognosis, the objectives are sometimes underestimated. However, several studies have shown that with the same rehabilitation, elderly patients recover as much as younger patients. The differences found are at least in part due to "less rehabilitation" of older stroke patients.

The different existing data lead us to the hypothesis that the verticalization of the elderly hemiplegic patient in acute phase would allow a better functional recovery.


Eligibility Criteria:
Inclusion Criteria:

* Ischemic or hemorrhagic stroke
* Age \> 70
* Modified Rankin Scale (MRS) pre stroke : 0 or 1
* Admission in the neuro vascular unit less than 48 hours after the onset of symptoms
* NIHSS Item 6 for lower extremity motor skills: 3 or 4
* Modified Functional Ambulation Classification : 0
* Affiliated to a social security scheme

Exclusion Criteria:

* History of stroke with motor sequencing limiting walking
* Arterial stenosis limiting the sunrise before D4 (identified by Doppler)
* Symptomatic orthostatic hypotension known or present in the acute phase
* Coma
* Patients who will be referred to a structure (UNV or other) outside the department
* Fracture, orthopedic disorder or any other complication preventing verticalization
* Refusal of the patient to participate in the study or to be verticalized
* Patients under guardianship
* Patients deprived of their liberty by an administrative decision
A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

This is a single-center, cross-over comparison parallel group randomized trial designed to evaluate the efficacy and safety of Ganfort compared to Duotrav for a treatment period of 8 weeks each.


Eligibility Criteria:
Inclusion Criteria:

1. Visual acuity 6/60 or better
2. Patients who are controlled (IOP \< 21 mmHg) on non-fixed combination of Latanoprost \& Timolol for at least 3 months before the baseline visit and
3. Patients on mono-therapy either Latanoprost or Timolol who are eligible for dual therapy being not satisfactorily controlled (IOP\>21mmHG)

Exclusion Criteria:

1. Angle closure glaucoma
2. Neovascular Galucoma
3. Secondary open angle glaucoma
4. Ocular infection/inflammation within 3 months
5. Ocular surgery within 3 months
6. History of Refractive surgery
7. Argon laser trabeculoplasty/Selective laser trabeculoplasty
8. Pregnancy/nursing
9. Hypersensitivity to benzalkonium chloride or to any other components of the trial drugs solution.
10. Patients in whom beta-blockers are contraindicated
11. Patients on any drugs known to affect IOP.
An Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300)

This is an observational study of patients with Primary Mitochondrial Disease with either signs or symptoms suggestive of myopathy. The Investigator will identify potential patients through existing medical records and one on-site visit.

An observational study of patients with presumed Primary Mitochondrial Disease designed to better characterize and correlate symptoms and signs of myopathy and genetic test results and the use of commonly prescribed treatments. The study will help define and identify a subject population for a future trial of an investigational product to treat primary mitochondrial disease associated with signs and symptoms of myopathy.

Eligibility Criteria:
Inclusion Criteria:

* Willing and able to provide a signed informed consent form (ICF) prior to participation in any-trial related procedures
* Patient has clinical presentation of PMD with either signs or symptoms suggestive of myopathy
* Patient is ambulatory and able to attempt 6MWT

Exclusion Criteria:

* Patient has symptoms of PMD due to secondary mitochondrial dysfunction
* Patient has had prior exposure to elamipretide
* Patient does not have the cognitive capacity to understand and complete all study assessments
* Patient has a medical history of severe renal impairment
* History of active alcoholism or drug addiction during the year before enrollment
Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care

In this clinical trial we want to investigate the clinical benefit of a complementary therapy using therapeutical modalities of the traditional chinese medicine in patients suffering from advanced cancer.

After giving informed consent, the participants will be randomized into two groups (1:1). Both groups will receive standard care while one group will additionally be assigned to a practitioner of traditional Chinese medicine (TCM) who will deliver a individual treatment according to the needs of the participant (pragmatic approach).

Outcome measures will be monitored over the course of eight weeks.

Eligibility Criteria:
Inclusion Criteria:

* One of the following tumor entities

  * Colorectal cancer (CRC)
  * Lung cancer (SCLC, NSCLC)
  * Breast cancer (BC)
  * Pancreas/Cholangiocellular cancer
* Best supportive care (i.e., no currently ongoing tumor-specific therapy)

  o Exception: palliative anti-hormonal therapy or palliative radiotherapy
* Performance status: ECOG 0 to 2
* Estimated life expectancy \> 4 months

Exclusion Criteria:

* Any serious concomitant systemic disorder
* Pregnancy or breast-feeding
* Impossibility to attend TCM practices in Graz
* Incapacity to comply/consent
* Language barrier
* Brain metastases
Identification of Human Biomarkers Predictive of Diabetes Remission in Type 2 Diabetes Patient (BARIAKINES)

This study focuses on identifying potentially predictive human circulating adipocyte and muscle biomarkers of diabetes remission after bariatric surgery in obese type 2 diabetic (T2D) subjects.

The study team at the Institute of Metabolic and Cardiovascular Diseases has recently identified several potential biomarkers (secreted by skeletal muscle and adipose tissue) of glucose homeostasis control using secretomic and metabolomic analyses. The goal of this study is to assess whether the addition of 9 adipocytes and myocytes plasma level could be associated with type 2 diabetes remission one year after bariatric surgery and would improve established clinical models of prediction of diabetes remission.

Thus, obese type 2 diabetes patients undergoing bariatric surgery will have 2 blood samples, a muscle sample and one adipose tissue sample withdrawn during the study. From those samples, concentrations of 9 candidate proteins is measured : GDF6, INHBB, IL17B, TGFB2, TIMP1, VTN, MDK, GDF15, and apoM

Eligibility Criteria:
Inclusion Criteria:

* Obese patients of at least grade 2 (body mass index ≥ 35 kg/m²)
* Type 2 diabetics
* About to undergo bariatric surgery at the Toulouse University Hospital
* Affiliated or beneficiaries of a social security plan.
* Having provided a free, informed and written consent, signed

Exclusion Criteria:

* Type 1 diabetic subjects or Maturity-Onset Diabetes of the Youth.
* Pregnant and breastfeeding women.
* Vulnerable persons as defined in the Public Health Code: protected adults (guardianship, curators), unable to express their consent.
Evaluation of Efficacy and Safety of Insulin Glargine Injected by Needle-free Jet Syringe

Using CGMS to compare the blood sugar improvement and patient sensibility of insulin glargine injected with needle-free jet injector and conventional insulin pen

Compared with conventional pen, needle-free jet injection of insulin has faster flow rate and larger area of local subcutaneous absorption. The aim of this study was to investigate the effects of subcutaneous insulin glargine injection with needle-free jet injection and conventional pen on blood glucose profile of CGMS and safety in type 2 diabetic patients.

Eligibility Criteria:
Inclusion Criteria:

* volunteer to participate and be able to sign informed consent prior to the trial.
* patients with type 2 diabetes, aged 18-65 years old, meeting WHO1999 diagnostic criteria, have not used any hypoglycemic drugs. The dosage of insulin glargine (12-18 units) combined with oral medicationis, stable for more than 2 months.
* No acute complications such as diabetic ketoacidosis, diabetic hyperosmolar syndrome, etc.
* Subjects are able and willing to monitor peripheral blood sugar and regularity of diet and exercise.

Exclusion Criteria:

* Patients with insulin allergy.
* Impaired liver and kidney function with ALT 2.5 times higher than the upper limit of normal value;Serum creatinine was 1.3 times higher than the upper limit of normal.
* Drug abuse and alcohol dependence in the past 5 years.
* Systemic hormone therapy was used in the last three months.
* Patients with poor compliance and irregular diet and exercise.
* Patients with pregnancy, lactation or pregnancy intention.
* Any other obvious conditions or associated diseases determined by the researcher: such as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors and other diseases, other pancreatic diseases, history of mental diseases.
The Safety and Efficiency of Sildenafil in the Treatment of Severe Post-capillary Pulmonary Hypertension Caused by COPD

Over half of chronic obstructive pulmonary disease (COPD) patients develop pulmonary hypertension. The current therapy focuses only on the basic disease and there are a lot of controversies about the use of PAH target therapy in group 3 pulmonary hypertension. Our study is to explore whether sildenafil, a pulmonary arterial hypertension (PAH) target drug, could be efficient and safe in improving symptoms and survival of severe pulmonary hypertension caused by COPD.


Eligibility Criteria:
Inclusion Criteria:

* Stable for over 1 month
* mean pulmonary artery pressure ≥35mmHg, pulmonary wedge pressure≤ 15mmHg
* never received target therapy before

Exclusion Criteria:

* Patients with other serious respiratory diseases
* Patients with pulmonary hypertension other than group 3
* Patients with right heart hypertrophy or dysfunction not caused by chronic obstructive pulmonary diseases
* Patients with limited life expectancy
* Patients with history of tracheal intubation or stoke, acute coronary syndrome in 6 months
* Psychopath or addict
* Nonstable patients with type Ⅰor Ⅱ respiratory failure
* Patients with contraindication for sildenafil
* Patients in pregnancy or breastfeeding
Trials of Ventilation Assisted Substance Elimination Via the Lung - Ethanol (VASEL - Ethanol)

This prospective, randomized control trial will use passive, isocapnic hyperventilation, applied via the ClearMateTM device (Thornhill Medical, Inc) versus controls receiving standard of care supportive management for severe alcohol intoxication to assess for enhanced ethanol elimination kinetics.


Eligibility Criteria:
Inclusion Criteria:

* intoxicated requiring admission to an emergency unit

Exclusion Criteria:

* Liver or renal disease
Yoga 4 Body Image (Y4BI): Investigating the Impact of Yoga on Body Image and Eating Behaviours

The practice of yoga can positively impact body image, a psychological construct encompassing perceptual, emotional, cognitive, and behavioral aspects, which can be either positive or negative. Negative body image manifests as extreme dissatisfaction with one's body-a condition particularly common among young women-that places them at significant risk for developing Body Image Disorders (BIDs). In contrast, positive body image is characterized by an overall respect for one's body.

Current research on the impact of yoga on body image has several limitations, making it challenging to determine whether yoga practice truly has a positive effect on body image and to identify the mechanisms underlying this impact. To address these gaps, the present project aims to overcome the limitations of existing studies by investigating the impact of yoga on body image through quantitative methodologies and by exploring the mechanisms that drive this effect.

The project consists of two phases:

1. Investigating the impact of yoga on body image (both positive and negative) and eating behaviours in a population characterized by high levels of body dissatisfaction-young women.
2. Examining the psychological mechanisms underlying yoga's impact on body image, including increased interoceptive awareness, embodiment, and self-compassion, as well as a reduction in self-objectification.


Eligibility Criteria:
Inclusion Criteria:

* Females
* Age 18-35 years old

Exclusion Criteria:

* Regular yoga practice
* Pregnancy
* Medical conditions that preclude yoga practice (e.g., neurodegenerative diseases, recent injuries, rheumatic conditions)
* Full-blown body image disorder
S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma may help doctors learn more about changes that occur in DNA and identify biomarkers related to these diseases. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at blood and bone marrow samples from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma.

OBJECTIVES:

* Establish a serum, cell, and bone marrow tissue bank of prospectively collected samples from patients with monoclonal gammopathy of undetermined significance (MGUS), asymptomatic multiple myeloma, solitary plasmacytoma, or other plasma cell dyscrasias.
* Evaluate the feasibility of accruing patients with these diseases.
* Determine whether patterns of gene expression or cytogenetics exist that allow molecular delineation of MGUS subtypes.
* Characterize cellular and humoral immune response to known tumor antigens in these patients.
* Cryopreserve serum/T cells for future evaluation.
* Preliminarily identify biological correlates that may relate to progression to symptomatic disease.

OUTLINE: Patients are stratified according to diagnosis (monoclonal gammopathy of undetermined significance \[MGUS\] or other plasma cell dyscrasias vs asymptomatic multiple myeloma vs solitary plasmacytoma).

Blood and bone marrow samples are collected and analyzed for microarray analysis, cytogenetic analysis, and immunobiology studies.

Unused samples may be stored for future research studies.

Patients are followed periodically for 5 years.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Diagnosis of one of the following plasmaproliferative diseases:

  * Monoclonal gammopathy of undetermined significance (MGUS)
  * Asymptomatic multiple myeloma
  * Solitary plasmacytoma
  * Other plasma cell dyscrasias
* Disease does not require therapy
* Willing to submit research samples for gene expression analysis and immunologic assessment

PATIENT CHARACTERISTICS:

Age

* Not specified

Performance status

* Zubrod 0-2

Life expectancy

* Not specified

Hematopoietic

* Not specified

Hepatic

* Not specified

Renal

* Not specified

Other

* No other malignancy within the past 2 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or adequately treated stage I or II cancer from which the patient is currently in complete remission

PRIOR CONCURRENT THERAPY:

Biologic therapy

* No prior biologic therapy for this disease

Chemotherapy

* No prior chemotherapy for this disease

Endocrine therapy

* No prior endocrine therapy for this disease

Radiotherapy

* No prior radiotherapy for this disease

Surgery

* No prior surgery for this disease

Other

* Prior or concurrent bisphosphonates allowed
A Pilot Study Using Placenta Derived Decidual Stromal Cells for Toxicity and Inflammation With Special Focus to the Allogeneic Hematopoietic Cell Transplantation Setting

To evaluate safety and efficacy using decidual stromal cell therapy for toxicity and inflammation, with special focus on allogeneic hematopoietic cell transplantation patients. The hypothesis to be tested is that the cells are safe to infuse and that they have an anti-inflammatory and healing effect.

Patients with toxicity, inflammation or hemorrhages will receive decidual stromal cells at approximately 1x10\^6 cells/kg at one or more occasions at weekly intervals dependent on clinical response.

Eligibility Criteria:
Inclusion Criteria:

* Patients with toxicity, inflammation or hemorrhages.

Exclusion Criteria:

* None
Transumbilical Versus Transvaginal Specimen Retrieval at Minilaparoscopy

We hypothesise that pain at minilaparoscopy for gynecologic disease is reduced when transvaginal rather than transumbilical specimen extraction is accomplished. This would be due to the avoidance of a 10-mm port in the umbilicus. Visual analogue scale score of post-operative pain will be obtained and patients satisfaction will be asked at the 2-month postoperative visit.


Eligibility Criteria:
Inclusion Criteria:

* Adnexal Mass
* Benign Gynecologic Condition
* Laparoscopicb Surgery

Exclusion Criteria:

* Obliteration Of The Douglas Pouch
The Effect of a Low Glycemic Index Diet on Blood Sugar Control in Women With Gestational Hyperglycemia

The purpose of the study is to see if a low glycemic index diet will reduce blood sugar levels in pregnant women with high blood sugar levels.

Women with gestational hyperglycemia, including women with gestational diabetes and impaired glucose tolerance of pregnancy, consuming a low glycemic index (GI) diet will experience better blood glucose control thereby decreasing the risk associated complication(s).

Eligibility Criteria:
Inclusion Criteria:

* women with gestational hyperglycemia
* age between 18 and 45 inclusive
* willing and able to comply with protocol

Exclusion Criteria:

* \<18 or \>45 years of age
* other chronic or acute illness which affects carbohydrate metabolism
* known multiple pregnancy
* \>34 weeks gestation
* language barrier (no translator available)
Effects of Two-weeks of Time Restricted Feeding on Basal and Postprandial Metabolism in Healthy Men

In the modern era, food access is widely available and it is not uncommon for the time between breakfast and a late night snack to exceed 14 hours. The investigators are interested in studying whether limiting this window to 8 hours will have any beneficial effects of human health as has been demonstrated in animal models. Eight men were asked to restrict their energy intake window to between 8 am and 4 pm for two weeks whilst maintaining their habitual diet (quantity and composition). Improvements in skeletal muscle and whole-body insulin sensitivity were observed but these were potentially confounded by an average weight loss of 1 kg. Therefore an additional control group was recruited to follow a daily caloric deficit of \~400 kilocalories without changing the timing of intake.

All participants were monitored for a one week baseline period to establish their habitual physical activity and dietary patterns. This was done using food diaries, interstitial glucose monitors and a combined heart rate + accelerometer device. Participants consumed a standardised evening meal \~12h before visiting the laboratory to assess their metabolic response to a liquid test meal (1g/kg bodyweight dextrose and 0.4g/kg bodyweight protein) using the arterio-venous forearm balance model. Dual-energy X-ray absorptiometry scans, indirect calorimetry measurements and fasted and postprandial vastus lateralis biopsies were also obtained.

From the next day, participants either restricted their daily energy intake window to between 8 am and 4 pm or were prescribed a caloric deficit diet (\~400 kilocalories/day) for two weeks. Physical activity, interstitial glucose concentrations and dietary patterns were monitored throughout. After this, participants visited the laboratory again to assess changes in metabolism and body composition.

Eligibility Criteria:
Inclusion Criteria:

* Healthy male between 18 and 35 years old
* Body mass index between 18 and 27.5 kg.m\^-2
* Regular breakfast consumer, 5 or more days per week
* Moderate physical activity level (PAL between 1.6 and 2)

Exclusion Criteria:

* Smoking
* Any metabolic (e.g. diabetes), endocrine (e.g. hyperthyroidism) or cardiovascular (heart or blood) abnormalities including hypertension.
* Clinically significant abnormalities on screening including ECG abnormalities
* Routine medication that may alter cardiovascular function and blood flow (e.g. blood pressure-lowering drugs or drugs that cause hypertension)
* High alcohol consumption (Routinely \>4 units per day)
* Eating attitudes test (EAT-26) score \> 20
* On an energy-restricted diet
* Significant body mass fluctuation in previous 3 months (\>5%)